INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES

Provided herein is a composition, comprising: a plurality of nanoentities comprising an inner core surrounded by an outer shell, the outer shell comprising a polymer, the inner core comprising at least one hydrophobic compound, wherein the nanoentities comprise a pharmaceutical agent, the pharmaceutical agent is an antibody or a fragment thereof, and the antibody or the fragment thereof binds to an epitope of an activated mutated KRAS protein. These anti-KRAS antibodies formulated into particular nanoentities are able to be intracellular delivered and further, are able to perform their biological activity inside the cell, thus being useful in the treatment of cancer and other disease associated with a mutation in a KRAS gene. 本文提供了一种组合物，所述组合物包括：多个纳米实体，所述多个纳米实体包括被外壳包围的内核，所述外壳包括聚合物，所述内核包括至少一种疏水性化合物，其中所述纳米实体包括药剂，其中所述药剂是抗体或其片段，其中所述抗体或所述其片段与激活的突变KRAS蛋白的表位结合。调配成特定纳米实体的这些抗KRAS抗体能够被胞内递送，并且另外能够在细胞内部进行其生物活动，因而可用于治疗与KRAS基因的突变相关的癌症和其它疾病。